// App-Quantinova.ai

2573 : Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy

Researchers

Presenter

  • Daniel I. Nathan

Principal Investigators

  • Douglas Tremblay

  • Santiago Thibaud

  • John Mascarenhas

  • Janice L. Gabrilove

Medical Centers

  • Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

  • Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Acute lymphoblastic leukemia

  • Myelodysplastic Syndrome

  • Acute myelocytic leukemia

  • Polycythemia vera

  • Myelofibrosis

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • Vidaza

  • Ruxolitinib phosphate

  • Decitabine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved